It is expected to become the world’s first heavyweight iteration of a major item to be launched on the market

HONG KONG SAR - Media OutReach Newswire - 7 October 2024 - AIM Vaccine announced on the evening of October 6 that the company has received notification from the National Institutes for Food and Drug Control on the serum antibody test results of the phase III clinical trial of the iterative serum-free rabies vaccine.

Read more: Phase III clinical data of AIM Vaccine iterative serum-free rabies vaccine reaches preset goals